{
    "clinical_study": {
        "@rank": "51984", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Experimental", 
                "description": "Cohort A, advanced liver disease Group 1. Participants with cirrhosis and moderate hepatic impairment (CPT Class B) will be randomized to receive either 12 or 24 weeks of LDV/SOF plus RBV."
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Experimental", 
                "description": "Cohort A, advanced liver disease Group 2. Participants with cirrhosis and severe hepatic impairment (CPT Class C) will be randomized to receive either 12 or 24 weeks of LDV/SOF plus RBV."
            }, 
            {
                "arm_group_label": "Group 3", 
                "arm_group_type": "Experimental", 
                "description": "Cohort B, post-transplant Group 3. Participants without cirrhosis (fibrosis stage F0-F3) and with no evidence of hepatic decompensation will be randomized to receive either 12 or 24 weeks of LDV/SOF plus RBV."
            }, 
            {
                "arm_group_label": "Group 4", 
                "arm_group_type": "Experimental", 
                "description": "Cohort B, post-transplant Group 4. Participants with cirrhosis and mild hepatic impairment (CPT Class A) will be randomized to receive either 12 or 24 weeks of LDV/SOF plus RBV."
            }, 
            {
                "arm_group_label": "Group 5", 
                "arm_group_type": "Experimental", 
                "description": "Cohort B, post-transplant Group 5. Participants with cirrhosis and moderate hepatic impairment (CPT Class B) will be randomized to receive either 12 or 24 weeks of LDV/SOF plus RBV."
            }, 
            {
                "arm_group_label": "Group 6", 
                "arm_group_type": "Experimental", 
                "description": "Cohort B, post-transplant Group 6. Participants with cirrhosis and severe hepatic impairment (CPT Class C) will be randomized to receive either 12 or 24 weeks of LDV/SOF plus RBV."
            }, 
            {
                "arm_group_label": "Group 7", 
                "arm_group_type": "Experimental", 
                "description": "Cohort B, post-transplant Group 7. Participants with aggressive recurrent disease after transplant with evidence of cholestasis (fibrosing cholestatic hepatitis [FCH]) will be randomized to receive either 12 or 24 weeks of LDV/SOF plus RBV."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate ledipasvir/sofosbuvir (LDV/SOF) fixed-dose\n      combination (FDC) in participants with chronic genotype 1 or 4 hepatitis C virus (HCV)\n      infection. Participants will be randomized to receive 12 or 24 weeks of dosing with the\n      LDV/SOF FDC tablet+ribavirin (RBV)."
        }, 
        "brief_title": "Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic HCV Infection", 
        "condition_browse": {
            "mesh_term": "Liver Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Able to provide written informed consent\n\n          -  Chronic genotype 1 or 4 HCV infection\n\n          -  Normal ECG\n\n          -  Negative serum pregnancy test for female subjects\n\n          -  Male subjects and female subjects of childbearing potential must agree to use\n             contraception\n\n          -  Able to comply with the dosing instructions for study drug and able to complete the\n             study schedule of assessments, including all required post treatment visits\n\n        Exclusion Criteria\n\n          -  Serious or active medical or psychiatric illness\n\n          -  HIV or hepatitis B viral (HBV) infection\n\n          -  Stomach disorder that could interfere with the absorption of the study drug\n\n          -  Treated with an anti-HCV medication in the last 30 days\n\n          -  Any prior exposure to an HCV nonstructural protein (NS)5a-specific inhibitor\n\n          -  Use of human granulocyte-macrophage colony-stimulating factor (GM-CSF), epoetin alfa\n             or other therapeutic hematopoietic agents within 2 weeks of screening\n\n          -  History of clinically significant medical condition associated with other chronic\n             liver disease\n\n          -  Active spontaneous bacterial peritonitis at screening\n\n          -  Females who are breastfeeding\n\n          -  Infection requiring systemic antibiotics\n\n          -  Participated in a clinical study with an investigational drug or biologic within the\n             last 30 days\n\n          -  Active or history (last 6 months) of drug or alcohol abuse\n\n          -  History of organ transplant other than liver or kidney"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01938430", 
            "org_study_id": "GS-US-337-0123"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 2", 
                    "Group 3", 
                    "Group 4", 
                    "Group 5", 
                    "Group 6", 
                    "Group 7"
                ], 
                "description": "LDV 400 mg/SOF 90 mg FDC tablet administered orally once daily", 
                "intervention_name": "LDV/SOF FDC", 
                "intervention_type": "Drug", 
                "other_name": [
                    "GS-7977", 
                    "PSI-7977", 
                    "GS-5885"
                ]
            }, 
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 2", 
                    "Group 3", 
                    "Group 4", 
                    "Group 5", 
                    "Group 6", 
                    "Group 7"
                ], 
                "description": "RBV administered as 200 mg tablets (up to 1000-1200 mg) in a divided daily dose", 
                "intervention_name": "RBV", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85054"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92103"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20007"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32224"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66160"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lutherville", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21093"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48202"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55455"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Murray", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84107"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23219"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98101"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98104"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "7", 
        "official_title": "A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected With Chronic HCV Who Have Advanced Liver Disease or Are Post-Liver Transplant", 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Jill Denning", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Proportion of participants with sustained virologic response (SVR12), defined as HCV RNA < lower limit of quantitation (LLOQ) 12 weeks after last dose of study drug", 
                "safety_issue": "No", 
                "time_frame": "Posttreatment Week 12"
            }, 
            {
                "measure": "Proportion of participants who discontinue study drug due to an adverse event", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 24"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01938430"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of participants with sustained virologic response (SVR) at 2, 4, 8 and 24 weeks after discontinuation of therapy (SVR2, SVR4, SVR8 and SVR24)", 
                "safety_issue": "No", 
                "time_frame": "Posttreatment Weeks 2, 4, 8, and 24"
            }, 
            {
                "measure": "Proportion of participants who have HCV RNA < LLOQ by visit while on treatment", 
                "safety_issue": "No", 
                "time_frame": "Weeks 1, 2, 4, 6, 8, and 12"
            }, 
            {
                "measure": "HCV RNA levels and change from Day 1 through Week 8", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Weeks 1, 2, 4, 6, and 8"
            }, 
            {
                "measure": "Proportion of participants with virologic failure", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Posttreatment Week 24"
            }, 
            {
                "measure": "Change in model for end-stage liver disease (MELD) and Child-Pugh-Turcotte (CPT) scores", 
                "safety_issue": "No", 
                "time_frame": "Baseline through posttreatment Week 24"
            }, 
            {
                "description": "For those participants who have a liver transplant while on study, the proportion of participants with post-transplant virologic response (PTVR, defined as HCV RNA < LLOQ at 12 weeks post-transplant) will be summarized for participants in the Full Analysis Set (FAS) who have HCV RNA < LLOQ at their last observed HCV RNA prior to transplant.", 
                "measure": "Proportion of participants with post-transplant virologic response", 
                "safety_issue": "No", 
                "time_frame": "Posttreatment Week 12"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}